"To build long term customer relationships through value and excellent service."
(Cotton Filter Paper Dried Blood Spot variant 1)
High purity alpha cotton linter absorbent filter paper specifically formulated to yield a stable DNA, RNA and protein biomarker matrix for quantitative analysis. Surface texture, absorption rate and formation have been optimized for the Guthrie test. The formation is highly uniform and free from density irregularities.
The purity and formation of the material offers a highly reproducible platform for direct elution techniques. Meets or exceeds results obtained using conventional manual extraction methodology in comparison to known competitive commercial equivalents. Paper punches cleanly demonstrating minimal extraneous fibers. Material holds embossing with or without heat set and converts well for incorporation into diagnostic devices.
Uniform screen & felt sides with consistent density MD/CD - Manufacturing performed with RO water filtration system - This media demonstrates excellent lot-to-lot reproducibility - Material chemistries are verified against a standard using GC techniques prior to paper making process - CofC and CofA provided with shipments – Available as rolls, reels, sheets and semi-finished converted configurations.
Basis Weight (g/m2): 180
Caliper Thickness (mm): 0.44 – 0.47
Migration Distance (mm/10 min): 120 - 135
Surface: Smooth, bright white
Known Applications: Ideally suited as a specimen collection media for bioanalysis applications such as the collection of blood drops typical of the Guthrie test, a microbiological assay for the presence of phenylalanine, phenylpyruvate, and phenyllactate in blood or urine. Most notably the Guthrie test is used to screen newborn infants for phenylketonuria (PKU).
Known competitive grades*: GE Healthcare Whatman / S&S 903, Ahlstrom 226
*Use of competitive trademark or nomenclature for reference only. No ownership or license rights implied.
At time of publication no FDA 510k has been filed or approved. Suitability without such approval in clinical use is not implied. Incorporation in approved device shall be responsibility of OEMAs with all competitive material equivalencies, specific evaluation and testing should be thoroughly conducted.
©2014, I.W. Tremont Co. , Inc. Ver 01.14